Thursday, March 8, 2012

Enrollment in BioMarin late-stage rare disease trial swells

BioMarin Pharmaceutical Inc. completed enrollment in a 176-patient late-stage study of a drug designed to treat patients with the lysosomal storage disorder MPS IVA.
Novato-based BioMarin (NASDAQ: BMRN) said patients with the disorder, also called Morquio A Syndrome, have been enrolled at 31 sites in 17 countries.
Results of the Phase III study are expected in the fourth quarter, and BioMarin expects to file a new drug application in first-quarter 2013.

No comments:

Post a Comment